AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. 

CEO
Pascal Soriot
CEOPascal Soriot
Employees
96,100
Employees96,100
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1913
Founded1913
Employees
96,100
Employees96,100

AZN Key Statistics

Market cap
289.83B
Market cap289.83B
Price-Earnings ratio
27.96
Price-Earnings ratio27.96
Dividend yield
1.68%
Dividend yield1.68%
Average volume
2.28M
Average volume2.28M
High today
$187.37
High today$187.37
Low today
$184.01
Low today$184.01
Open price
$185.45
Open price$185.45
Volume
1.79M
Volume1.79M
52 Week high
$212.71
52 Week high$212.71
52 Week low
$132.32
52 Week low$132.32

Stock Snapshot

As of today, AstraZeneca(AZN) shares are valued at $184.74. The company's market cap stands at 289.83B, with a P/E ratio of 27.96 and a dividend yield of 1.7%.

On 2026-05-01, AstraZeneca(AZN) stock moved within a range of $184.01 to $187.37. With shares now at $184.74, the stock is trading +0.4% above its intraday low and -1.4% below the session's peak.

Trading activity shows a volume of 1.79M, compared to an average daily volume of 2.28M.

Over the past 52 weeks, AstraZeneca(AZN) stock has traded between a high of $212.71 and a low of $132.32.

Over the past 52 weeks, AstraZeneca(AZN) stock has traded between a high of $212.71 and a low of $132.32.

AZN News

TipRanks 8h
AstraZeneca Updates Total Voting Rights and Admits New Shares from Employee Schemes

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Benzinga 10h
AstraZeneca Prostate Drug Wins FDA Panel Backing As Breast Cancer Candidate Falters

FDA Panel Backs Truqap In Prostate Cancer The FDA panel voted 7-1, with one abstention, recognizing a favorable benefit-risk profile for AstraZeneca's Truqap (...

AstraZeneca Prostate Drug Wins FDA Panel Backing As Breast Cancer Candidate Falters
The Wall Street Journal 14h
AstraZeneca’s Breast-Cancer Candidate Drug Loses FDA Panel Vote

The offices of AstraZeneca in England. The FDA isn’t bound by the committee’s vote, but its takes its advice into consideration. Paul Ellis / Agence France-Pres...

AstraZeneca’s Breast-Cancer Candidate Drug Loses FDA Panel Vote

Analyst ratings

81%

of 31 ratings
Buy
80.6%
Hold
12.9%
Sell
6.5%

More AZN News

TipRanks 15h
FDA panel’s negative vote clouds AstraZeneca’s bid for camizestrant in advanced breast cancer

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

TipRanks 24h
AstraZeneca says FDA AdCom recommend Truqap in mHSPC

The company states: “The US Food and Drug Administration’s Oncologic Drugs Advisory Committee has recognised a favorable benefit risk profile for AstraZeneca’s...

TipRanks 1d
AstraZeneca: Buy Rating Reiterated as Camizestrant Upside and 18,000p Target Offset ODAC Setback

Jefferies analyst Michael Leuchten maintained a Buy rating on AstraZeneca today and set a price target of p18,000.00. Claim 55% Off TipRanks Unlock hedge fund-l...

TipRanks 1d
FDA panel votes 6-3 to reject AstraZeneca breast cancer drug, Bloomberg says

11:49 EDT FDA panel votes 6-3 to reject AstraZeneca (AZN) breast cancer drug, Bloomberg says Published first on TheFly – the ultimate source for real-time, mar...

TipRanks 2d
AstraZeneca upgraded to Buy from Hold at DZ Bank

DZ Bank analyst Elmar Kraus upgraded AstraZeneca (AZN) to Buy from Hold with a 16,400 GBp price target Published first on TheFly – the ultimate source for real...

Benzinga 2d
What's Going On With AstraZeneca Stock Wednesday? - AstraZeneca - Benzinga

...

What's Going On With AstraZeneca Stock Wednesday? - AstraZeneca - Benzinga
Benzinga 2d
AstraZeneca Flexes Cancer Drugs Performance, Pipeline Strength

The company posted revenue of $15.29 billion, up 13% year over year, or 8% at constant currency (CC), beating the consensus estimate of $14.94 billion. Adjusted...

AstraZeneca Flexes Cancer Drugs Performance, Pipeline Strength

People also own

Based on the portfolios of people who own AZN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.